144 related articles for article (PubMed ID: 23376717)
1. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.
Kaneko MK; Morita S; Tsujimoto Y; Yanagiya R; Nasu K; Sasaki H; Hozumi Y; Goto K; Natsume A; Watanabe M; Kumabe T; Takano S; Kato Y
Biochem Biophys Res Commun; 2013 Mar; 432(1):40-5. PubMed ID: 23376717
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Kato Kaneko M; Ogasawara S; Kato Y
Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Kaneko MK; Tian W; Takano S; Suzuki H; Sawa Y; Hozumi Y; Goto K; Yamazaki K; Kitanaka C; Kato Y
Biochem Biophys Res Commun; 2011 Mar; 406(4):608-13. PubMed ID: 21352804
[TBL] [Abstract][Full Text] [Related]
4. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
Kato Y
Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
[TBL] [Abstract][Full Text] [Related]
5. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation.
Kato Y; Kaneko MK
Biochem Biophys Res Commun; 2013 Apr; 433(4):374-8. PubMed ID: 23524262
[TBL] [Abstract][Full Text] [Related]
6. Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations.
Kaneko MK; Tsujimoto Y; Hozumi Y; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):224-8. PubMed ID: 23750482
[TBL] [Abstract][Full Text] [Related]
7. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma.
Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y
Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205
[TBL] [Abstract][Full Text] [Related]
8. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
Kato Y; Natsume A; Kaneko MK
Biochem Biophys Res Commun; 2013 Mar; 432(4):564-7. PubMed ID: 23485467
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
[TBL] [Abstract][Full Text] [Related]
10. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
Ogasawara S; Kaneko MK; Tsujimoto Y; Liu X; Kato Y
Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):377-81. PubMed ID: 24328739
[TBL] [Abstract][Full Text] [Related]
11. Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants.
Dogan S; Frosina D; Geronimo JA; Hernandez E; Mohanty A; Bale T; Hechtman JF; Arcila ME; Hameed MR; Jungbluth AA
Hum Pathol; 2020 Dec; 106():45-53. PubMed ID: 33017591
[TBL] [Abstract][Full Text] [Related]
12. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.
Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A
J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.
Liu X; Kato Y; Kaneko MK; Sugawara M; Ogasawara S; Tsujimoto Y; Naganuma Y; Yamakawa M; Tsuchiya T; Takagi M
Cancer Med; 2013 Dec; 2(6):803-14. PubMed ID: 24403254
[TBL] [Abstract][Full Text] [Related]
15. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
[TBL] [Abstract][Full Text] [Related]
16. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
[TBL] [Abstract][Full Text] [Related]
17. A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.
Catteau A; Girardi H; Monville F; Poggionovo C; Carpentier S; Frayssinet V; Voss J; Jenkins R; Boisselier B; Mokhtari K; Sanson M; Peyro-Saint-Paul H; Giannini C
Acta Neuropathol Commun; 2014 Jun; 2():58. PubMed ID: 24889502
[TBL] [Abstract][Full Text] [Related]
18. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Takano S; Tian W; Matsuda M; Yamamoto T; Ishikawa E; Kaneko MK; Yamazaki K; Kato Y; Matsumura A
Brain Tumor Pathol; 2011 Apr; 28(2):115-23. PubMed ID: 21344322
[TBL] [Abstract][Full Text] [Related]
19. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
[TBL] [Abstract][Full Text] [Related]
20. Study of mutations in IDH1 and IDH2 genes in a sample of gliomas from Colombian population.
Ricaurte O; Neita K; Valero D; Ortega-Rojas J; Arboleda-Bustos CE; Zubieta C; Penagos J; Arboleda G
Biomedica; 2018 May; 38(0):86-92. PubMed ID: 29874711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
